- Home
- RPRX vs FCNCA Comparison
RPRX vs FCNCA Comparison
Compare RPRX & FCNCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RPRX | FCNCA |
|---|---|---|
| Founded | 1996 | 1898 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 25.0B |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | RPRX | FCNCA |
|---|---|---|
| Price | $58.55 | $2,266.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $51.40 | ★ $2,199.64 |
| AVG Volume (30 Days) | ★ 2.9M | 70.4K |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | ★ 1.90% | 0.43% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.71 | ★ 97.95 |
| Revenue | $2,378,193,000.00 | ★ $9,541,000,000.00 |
| Revenue This Year | $38.63 | $3.43 |
| Revenue Next Year | $4.73 | N/A |
| P/E Ratio | $83.41 | ★ $23.19 |
| Revenue Growth | ★ 5.06 | N/A |
| 52 Week Low | $34.63 | $1,625.08 |
| 52 Week High | $60.44 | $2,289.99 |
Technical Indicators
Market Signals| Indicator | RPRX | FCNCA |
|---|---|---|
| Relative Strength Index (RSI) | 53.25 | 62.75 |
| Support Level | $55.66 | $2,049.02 |
| Resistance Level | $58.84 | $2,289.99 |
| Average True Range (ATR) | 1.42 | 43.12 |
| MACD | -0.11 | 5.27 |
| Stochastic Oscillator | 46.94 | 82.20 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About FCNCA First Citizens BancShares Inc.
First Citizens is a US regional bank with total assets of around $236 billion as of March 31, 2026. Headquartered in Raleigh, North Carolina, First Citizens' largest markets are North Carolina, South Carolina, and California. The bank has a track record of acquiring troubled banks from the FDIC, such as Silicon Valley Bridge Bank in 2023, which doubled its asset base. First Citizens offers products and services across retail, commercial, wealth management, and railcar leasing. First Citizens derived over 95% of its earnings from banking and less than 5% from railcar leasing in 2025.